Advanced Proteome Therapeutics Inc. reported that its scientists have invented new technologies to improve the safety and performance of antibody drug conjugates (ADCs). All current ADCs continue to cause off-target toxicities through toxin activity on healthy cells. APTI's new technologies are designed to complement APTI's ADC conjugation technology, and further prevent toxin delivery and activation in non-target healthy cells. These technologies will provide APTI with a suite of technologies that will increase both company attractiveness as a licensor of ADC technologies and further company longer term goal of developing wholly owned best in class ADCs. A particular opportunity will arise as the first ADCs start to come off patent; these drugs continue to have both significant sales and toxicities; applying company technologies in a biobetter approach may result in increased efficacy and decreased toxicity. Company expect intellectual property to be filed in the coming weeks and will provide an update and further information at that time. As previously announced, APTI's scientists have identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease and APTI has filed patents to protect company inventions. Company have now successfully synthesized the first of these and have produced quantities suitable for testing. Initial internal testing has taken longer than expected due to issues in test method validation. In the context of the significant inventions described above and recent news of vaccines with high efficacy nearing approval, APTI has chosen to deprioritize this project. Company continue to believe that SARS-CoV-2 antivirals are an unmet need and the inventions from this project continue to hold value both for SARS-CoV-2 and other applications. APTI plans to continue efforts to realize this value when resources are available. However, the above noted additions to company ADC technologies will have a far greater influence on company valuation, and thus must be prioritized. Previously announced collaboration with Dr. Brian Zeglis at the City University of New York to test APTI's site specific conjugation technology in the rapidly growing field of antibody radioisotope conjugates (ARCs) is progressing as planned. Company now have initial data demonstrating key characteristics of the construct built with APTI conjugation technology including superior homogeneity, consistent payload to antibody ratio, high stability and maintained antibody binding affinity. The next step of the project will be PET imaging and evaluation of in vivo bio-distribution in a single dose study. In totality, this project will provide valuable data about the impact of APTI site-selective conjugation technology on in vivo antibody behavior. This data could support development of ARCs for imaging purposes and may be inferred to apply to behavior of therapeutic antibody drug conjugates.